[go: up one dir, main page]

BRPI0717035B8 - moduladores de benzotriazol cinase - Google Patents

moduladores de benzotriazol cinase

Info

Publication number
BRPI0717035B8
BRPI0717035B8 BRPI0717035A BRPI0717035A BRPI0717035B8 BR PI0717035 B8 BRPI0717035 B8 BR PI0717035B8 BR PI0717035 A BRPI0717035 A BR PI0717035A BR PI0717035 A BRPI0717035 A BR PI0717035A BR PI0717035 B8 BRPI0717035 B8 BR PI0717035B8
Authority
BR
Brazil
Prior art keywords
benzotriazole
kinase modulators
modulators
kinase
jnk
Prior art date
Application number
BRPI0717035A
Other languages
English (en)
Inventor
Sidduri Achyutharao
Michoud Christophe
Michael Goldstein David
Gong Leyi
Solang Palmer Wylie
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0717035A2 publication Critical patent/BRPI0717035A2/pt
Publication of BRPI0717035B1 publication Critical patent/BRPI0717035B1/pt
Publication of BRPI0717035B8 publication Critical patent/BRPI0717035B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

moduladores de benzotriazol cinase. a presente invenção refere-se a novos derivados de benzotriazol de fórmula (i) em que r1, r2, r3, e m são como definidos na descrição e nas reivindicações, bem como sais fisiologicamente aceitáveis destes. estes compostos são moduladores de jnk e cdk.
BRPI0717035A 2006-09-08 2007-08-30 moduladores de benzotriazol cinase BRPI0717035B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84309006P 2006-09-08 2006-09-08
US60/843,090 2006-09-08
PCT/EP2007/059040 WO2008028860A1 (en) 2006-09-08 2007-08-30 Benzotriazole kinase modulators

Publications (3)

Publication Number Publication Date
BRPI0717035A2 BRPI0717035A2 (pt) 2014-11-25
BRPI0717035B1 BRPI0717035B1 (pt) 2021-05-04
BRPI0717035B8 true BRPI0717035B8 (pt) 2021-05-25

Family

ID=38893293

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717035A BRPI0717035B8 (pt) 2006-09-08 2007-08-30 moduladores de benzotriazol cinase

Country Status (17)

Country Link
US (1) US8962622B2 (pt)
EP (1) EP2066319B1 (pt)
JP (1) JP5325783B2 (pt)
KR (1) KR101177729B1 (pt)
CN (1) CN101511359B (pt)
AR (1) AR062666A1 (pt)
AT (1) ATE543498T1 (pt)
AU (1) AU2007293917B2 (pt)
BR (1) BRPI0717035B8 (pt)
CA (1) CA2662998C (pt)
CL (1) CL2007002572A1 (pt)
ES (1) ES2378577T3 (pt)
IL (1) IL197015A (pt)
MX (1) MX2009002229A (pt)
PE (1) PE20080659A1 (pt)
TW (1) TW200819440A (pt)
WO (1) WO2008028860A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
JP5179509B2 (ja) 2006-12-08 2013-04-10 エフ．ホフマン−ラ ロシュ アーゲー 置換ピリミジン類及びｊｎｋモジュレーターとしてのこれらの使用
CA2701275C (en) * 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
EP2283009B1 (en) * 2008-05-16 2012-08-29 F. Hoffmann-La Roche AG Inhibitors of jnk
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
JP5518905B2 (ja) 2009-02-24 2014-06-11 エフ．ホフマン−ラ ロシュ アーゲー ＪＮＫモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン
AU2010283769B2 (en) * 2009-08-10 2015-09-17 F. Hoffmann-La Roche Ag Inhibitors of JNK
JP5916719B2 (ja) * 2010-06-04 2016-05-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｊｎｋの阻害剤として有用な２−アミノ−ピリミジン誘導体
KR20130091308A (ko) * 2010-06-04 2013-08-16 에프. 호프만-라 로슈 아게 Jnk 억제제
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
KR101860971B1 (ko) * 2011-02-09 2018-07-05 더루우브리졸코오포레이션 아스팔텐 분산제 함유 윤활 조성물
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
ES2694829T3 (es) 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
PL3013353T3 (pl) 2013-06-26 2021-09-20 Xigen Inflammation Ltd. Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza
KR20170003553A (ko) 2014-04-04 2017-01-09 사이로스 파마수티컬스, 인크. 사이클린-의존성 키나제 7(cdk7)의 저해제
JP2017518333A (ja) * 2014-06-16 2017-07-06 アリンキー バイオファーマＡｌｌｉｎｋｙ Ｂｉｏｐｈａｒｍａ 神経系の変性疾患を治療及び予防するためのｐ３８及びｊｎｋ ｍａｐｋ阻害剤
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
CN108117523B (zh) * 2016-11-29 2021-05-07 上海医药工业研究院 卤代尿嘧啶类化合物的制备方法
SMT202100553T1 (it) 2017-04-24 2021-11-12 Aurigene Discovery Tech Ltd Metodi d'uso per derivati benzotriazolici trisostituiti come inibitori di diidroorotato ossigenasi
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
BR112023004249A2 (pt) * 2020-09-15 2023-04-04 Mitsubishi Tanabe Pharma Corp Sal composto de triazina, forma cristalina do mesmo e método de produção do mesmo
CN114456126A (zh) * 2022-02-26 2022-05-10 郑州萃智医药科技有限公司 一种化合物的合成方法
CN115677595B (zh) * 2022-10-26 2024-06-14 江苏睿实生物科技有限公司 一种2,4,5-三氯嘧啶的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
WO2001000207A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CA2567662C (en) 2004-06-10 2012-11-27 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
JP2009533327A (ja) 2006-03-22 2009-09-17 バーテックス ファーマシューティカルズ インコーポレイテッド 増殖性疾患を処置するためのｃ−ＭＥＴキナーゼ阻害剤

Also Published As

Publication number Publication date
CN101511359B (zh) 2012-09-05
AU2007293917B2 (en) 2013-01-31
JP2010502668A (ja) 2010-01-28
TW200819440A (en) 2008-05-01
WO2008028860A1 (en) 2008-03-13
JP5325783B2 (ja) 2013-10-23
KR20090040908A (ko) 2009-04-27
PE20080659A1 (es) 2008-05-17
IL197015A0 (en) 2009-11-18
KR101177729B1 (ko) 2012-09-07
AU2007293917A1 (en) 2008-03-13
BRPI0717035B1 (pt) 2021-05-04
ES2378577T3 (es) 2012-04-16
IL197015A (en) 2013-12-31
AR062666A1 (es) 2008-11-26
US20080103142A1 (en) 2008-05-01
US8962622B2 (en) 2015-02-24
CA2662998C (en) 2015-10-06
CN101511359A (zh) 2009-08-19
CA2662998A1 (en) 2008-03-13
MX2009002229A (es) 2009-03-16
CL2007002572A1 (es) 2008-04-18
ATE543498T1 (de) 2012-02-15
EP2066319A1 (en) 2009-06-10
BRPI0717035A2 (pt) 2014-11-25
EP2066319B1 (en) 2012-02-01

Similar Documents

Publication Publication Date Title
BRPI0717035B8 (pt) moduladores de benzotriazol cinase
BRPI0911035A2 (pt) ativadores de pirrolidinona glicoquinase
ECSP088549A (es) Nuevos derivados de pirrol fusionado
BRPI0518758A2 (pt) compostos de acetamida como fungicidas
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
BR112012006531A2 (pt) derivados de imidazopirimidina ou imidazopiridina como inibidores da fosfodiesterase 10a.
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BRPI0511621A (pt) compostos orgánicos
BR112012010186A2 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3.
BRPI0617167B8 (pt) sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
BR112012017580A2 (pt) derivados de heteroarila contendo nitrogênio
NO20083669L (no) 4-aryl-2amino-pyrimidiner eller 4-aryl-2-aminoalkylpyrimidiner som jak-2-modulatorer og fremgangsmater for anvendelse derav
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
CR9602A (es) Nuevos derivados de 2,4-dianilinpirimidinas, su preparacion, como medicamentos, composiciones farmaceuticas y particularmente como inhibidores de ikk
TW200833324A (en) Sulfonamide derivatives
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
BRPI0817223B8 (pt) inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação
CR11176A (es) Formulaciones liquidas solubles de sales amonicas de quinclorac
BR112014004522A2 (pt) moduladores de pde10
CR11157A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
BR112014006248A2 (pt) compostos de triazolopiridina como inibidores de pde10a
NI201000188A (es) Derivados de piperidina 3,4-sustituida como inhibidores de renina.
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF